Aceruloplasminemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Aceruloplasminemia is a rare autosomal recessive neurodegenerative disorder characterized by the complete absence or severe deficiency of ceruloplasmin in the blood. Ceruloplasmin
is a copper-transporting enzyme encoded by the CP gene, and its deficiency leads to systemic iron overload, particularly affecting the brain, liver, and retina.[1]
Aceruloplasminemia is caused by homozygous or compound heterozygous mutations in the CP gene (chromosome 3q24), which encodes ceruloplasmin—a 1046-amino acid glycoprotein
synthesized primarily in the liver. Ceruloplasmin is the main copper transporter in plasma and plays a critical role in iron metabolism through its ferroxidase activity.[2]
The disorder follows an autosomal recessive inheritance pattern. Over 40 pathogenic variants have been identified, including nonsense mutations, deletions, and splice-site
mutations that result in a complete loss or severe reduction of functional ceruloplasmin.[3]
Ceruloplasmin possesses ferroxidase activity that converts toxic Fe[2]⁺ (ferrous iron) to Fe[3]⁺
(ferric
iron), which can then be bound by transferrin for safe transport. In aceruloplasminemia, this conversion is impaired, leading to:
- Reduced iron export: Iron cannot be efficiently exported from cells, causing intracellular iron accumulation
- Increased free radicals: Fe[2]⁺ generates hydroxyl radicals through Fenton chemistry, causing oxidative damage
- Tissue iron overload: Iron accumulates in the brain (particularly the basal ganglia, thalamus, and cerebellum), liver, pancreas, and retina[4]
The iron accumulation in the brain leads to:
- Neuronal loss in the basal ganglia and cerebellum
- Demyelination and axonal degeneration
- Astrogliosis (reactive astrocytosis)
- Microglial activation and neuroinflammation
The disease exemplifies the critical role of ferroxidase activity in neuronal survival, and serves as a model for understanding iron-induced neurodegeneration.[5]
Neurological manifestations typically present in adulthood (third to fourth decade), though some patients show earlier onset:
- Movement disorders: Tremor, ataxia, chorea, dystonia, and parkinsonism
- Cognitive decline: Progressive dementia resembling Alzheimer's or Huntington's Disease
- ** Psychiatric symptoms**: Depression, anxiety, personality changes
- Seizures: Focal or generalized seizures may occur
- Visual disturbances: Retinal degeneration and macular atrophy leading to progressive vision loss[6]
- Anemia: Microcytic, hypochromic anemia despite iron overload (paradoxical iron sequestration)
- Hepatomegaly: Liver enlargement due to hepatic iron accumulation
- Diabetes mellitus: Iron-induced pancreatic β-cell dysfunction
- Retinal degeneration: Progressive retinopathy with bone spicule pigmentation
- Absent or markedly reduced ceruloplasmin (<5 mg/dL; normal: 20-60 mg/dL)
- Low serum copper (<10 μg/dL; normal: 70-140 μg/dL)
- Elevated serum ferritin (>1000 ng/mL)
- Transferrin saturation near 100%
- Absent serum ferroxidase activity
MRI reveals characteristic T2 hypointensity in the:
- Globus pallidus
- Putamen
- Thalamus
- Cerebellar dentate nuclei
- Retina (on MR retina imaging)
These findings reflect iron deposition and help differentiate aceruloplasminemia from other forms of neurodegeneration with brain iron accumulation (NBIA).[7]
- Clinical suspicion: Adult-onset movement disorder with cognitive decline and anemia
- Laboratory confirmation:
- Ceruloplasmin <5 mg/dL
- Serum copper <10 μg/dL
- Ferritin >1000 ng/mL
- Genetic testing: Biallelic pathogenic variants in CP gene
- Neuroimaging: MRI showing iron deposition in basal ganglia and cerebellum
- Other NBIA disorders (PKAN, PLAN, FA2H, WDR45)
- Hemochromatosis
- Wilson's Disease
- Friedreich's Ataxia
Iron chelation is the primary treatment approach:
- Deferoxamine: Subcutaneous infusion; may reduce brain iron levels but limited CNS penetration
- Deferasirox: Oral chelator; better CNS penetration; shown to reduce MRI signal abnormalities
- Combination therapy: Deferasirox with occasional deferoxamine may provide optimal iron removal
- Iron supplementation avoidance: Restrict iron intake; avoid iron-containing vitamins
- Antioxidant therapy: Coenzyme Q10, vitamin E may help mitigate oxidative damage
- Neuroprotective agents: Under investigation
- Gene therapy: Potential future approach to restore ceruloplasmin expression
- Regular monitoring of ferritin, liver function, and neurological status
- Diabetes management per standard protocols
- Physical therapy for movement disorders
- Cognitive and psychiatric support
With early diagnosis and aggressive chelation therapy, disease progression can be slowed or partially reversed. Patients diagnosed and treated in the presymptomatic or early
symptomatic phase have better outcomes. Without treatment, the disease leads to severe neurological disability and premature death.[8]
Aceruloplasminemia is extremely rare, with an estimated prevalence of 1 in 2,000,000. Higher prevalence has been reported in populations with consanguinity. The disease affects
both males and females equally.[9]
Cp knockout mice recapitulate key features of human aceruloplasminemia, including brain iron accumulation, ataxia, and retinal degeneration. These models have been instrumental in
understanding disease pathogenesis and testing therapeutic interventions.[10]
Current research focuses on:
- Developing brain-penetrant chelators
- Understanding genotype-phenotype correlations
- Exploring gene therapy approaches
- Identifying biomarkers for treatment response
- Investigating the role of ceruloplasmin in normal brain aging
The study of Aceruloplasminemia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A. 1995;92(7):2539-2543. DOI:10.1073/pnas.92.7.2539
- Hellman NE, Schaefer M, Gehrke S, et al. Ceruloplasmin gene mutations lead to abnormal iron metabolism and systemic iron overload. J Neural Transm Suppl. 2000;(58):75-82. DOI:10.1007/978-3-7091-6281-9_7
- Kono S, Miyajima H. Aceruloplasminemia. In: Valle D, Beaudet AL, Vogelstein B, et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2014.
- Miyajima H, Kohno S, Takahashi Y, et al. Estimation of the gene frequency of aceruloplasminemia in Japan. J Neurol Sci. 1999;164(2):163-166. DOI:10.1016/s0022-510x(9900071-6
- ress MN, Weder B, Koster T, et al. Iron metabolism and neurodegeneration: prospective therapeutic approaches to aceruloplasminemia. Free Radic Biol Med. 2019;133:194-203. DOI:10.1016/j.freeradbiomed.2018.10.451
- Miyajima H. Aceruloplasminemia. Neuropathology. 2015;35(1):83-90. DOI:10.1111/neup.12154
- Honda K, Kono S, Miyajima H, et al. Serial MRI findings in aceruloplasminemia. J Neurol Sci. 2010;297(1-2):118-120. DOI:10.1016/j.jns.2010.06.022
- Finkenstedt A, Wolf E, Höfner G, et al. Long-term effects of deferasirox therapy on iron overload in aceruloplasminemia. Haematologica. 2010;95(10):1749-1753. DOI:10.3324/haematol.2009.020651
- Skidmore CJ, Oliver RW, Balani A, et al. Aceruloplasminemia: a rare cause of neurodegeneration with brain iron accumulation. J Neurol Sci. 2021;420:117247. DOI:10.1016/j.jns.2020.117247
- Jeong SY, Buss EG, Williams CD, et al. The role of ceruloplasmin in systemic iron metabolism. Semin Hematol. 2022;59(2):83-93. DOI:10.1053/j.seminhematol.2022.02.006## See Also
-
-
-
-
-
-